Last reviewed · How we verify
Ramipril + Felodipine
This combination lowers blood pressure by blocking angiotensin II formation (ramipril) and relaxing blood vessel smooth muscle (felodipine).
This combination lowers blood pressure by blocking angiotensin II formation (ramipril) and relaxing blood vessel smooth muscle (felodipine). Used for Hypertension.
At a glance
| Generic name | Ramipril + Felodipine |
|---|---|
| Sponsor | Sanofi |
| Drug class | ACE inhibitor + calcium channel blocker combination |
| Target | Angiotensin-converting enzyme (ACE) and L-type voltage-gated calcium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ramipril is an ACE inhibitor that prevents conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Felodipine is a dihydropyridine calcium channel blocker that directly relaxes vascular smooth muscle by blocking L-type calcium channels. Together, they provide complementary antihypertensive effects with different mechanisms of action.
Approved indications
- Hypertension
Common side effects
- Cough
- Headache
- Dizziness
- Peripheral edema
- Fatigue
- Flushing
- Palpitations
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- Efficacy and Safety of the Combination of Valsartan Plus Amlodipine in Hypertensive Patients Not Adequately Responding to the Combination Therapy With Ramipril Plus Felodipine (PHASE3)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
- China Medical University Hospital (CMUH) Triapin Listing (PHASE4)
- Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ramipril + Felodipine CI brief — competitive landscape report
- Ramipril + Felodipine updates RSS · CI watch RSS
- Sanofi portfolio CI